Need professional-grade analysis? Visit stockanalysis.com
$2.97B
N/A
N/A
N/A
Kailera Therapeutics, Inc. Common Stock (KLRA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $22.93, up 6.80% from the previous close.
Over the past year, KLRA has traded between a low of $16.00 and a high of $26.00. The stock has gained 43.3% over this period. It is currently 11.8% below its 52-week high.
Kailera Therapeutics, Inc. Common Stock has a market capitalization of $2.97B.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Side-by-side comparison against top Healthcare peers.